Tag
The TARGET-D trial investigated whether vitamin D supplementation, titrated to achieve serum levels >40-80 ng/mL, reduces major adverse cardiovascular events after myocardial infarction but found no significant benefit in the primary com
This review synthesizes evidence on colchicine’s efficacy in secondary stroke prevention, emphasizing the impact of concomitant atherosclerosis on outcomes from the CONVINCE trial and meta-analyses.
JCAD, a junctional protein, independently predicts major adverse cardiovascular events (MACE) in acute coronary syndrome (ACS) patients with residual lipid and inflammatory risks, suggesting a key role in coagulation and fibrinolysis and a
GLP-1 receptor agonists significantly reduce atherosclerosis progression, inflammatory biomarkers, and cardiovascular events independent of glycaemic control and obesity status, evidenced by robust preclinical and large-scale clinical data.
A large retrospective cohort study of 143,517 patients reveals that non-eosinophilic acute exacerbations of COPD carry a significantly higher one-year risk of major adverse cardiovascular events compared with eosinophilic exacerbations, sug
Researchers developed and validated ADAPT-CEC, an artificial intelligence algorithm that can adjudicate cardiovascular events across different trial definitions. A hybrid approach combining AI with selective human review achieved 95.6% accu
The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.
Recent research reveals glipizide, a common diabetes drug, increases cardiovascular risks compared to DPP-4 inhibitors. This challenges assumptions about sulfonylureas, urging personalized treatment considering heart health alongside glycem